FDA and Manufacturers of Accutane and its Generics to Implement iPLEDGE Program on March 1, 2006

FDA and Manufacturers of Accutane and its Generics to Implement iPLEDGE Program on March 1, 2006: "The iPLEDGE program, a strengthened risk management program to educate women about the risk of becoming pregnant while taking isotretinoin (Accutane and its generics), a drug to treat severe recalcitrant nodular acne, will be implemented on March 1, 2006, as planned. This comprehensive program seeks to reduce the risk of inadvertent pregnancy exposure by tightly linking negative pregnancy testing with dispensing of isotretinoin. "